Since the identification of the hepatitis C virus, great strides have been made in the
development of an antiviral therapy. As a crucial mediator of the innate antiviral immune …

Approximately 4 million persons in the United States and probably more than 100 million
persons worldwide are infected with hepatitis C virus. The virus has the unique ability to …

Background Only 15 to 20 percent of patients with chronic hepatitis C have a sustained
virologic response to interferon therapy. We compared the efficacy and safety of …

Hepatitis C virus (HCV) accounts for approximately 20% of cases of acute hepatitis, 70% of
chronic hepatitis, and 30% of end-stage liver disease in the United States. The acute …

Importance The efficacy of directly acting antiviral agents in interferon-free regimens for the
treatment of chronic hepatitis C infections needs to be evaluated in different populations …

Background Interferon alfa is the only effective treatment for patients with chronic hepatitis C.
Forty percent of patients have an initial response to this therapy, but most subsequently …

Chronic viral hepatitis is the principal cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in the world and now ranks as the chief reason for liver …

In view of the findings that high hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is
associated with increased risk of chronic hepatitis B (CHB)–related complications, disease …

Background & Aims: Fibrosis is the hallmark of hepatic cirrhosis, worsening of which is
probably the best surrogate marker for progression of chronic liver disease. We evaluated a …

Ribavirin, an antiviral drug discovered in 1972, is interesting and important for three
reasons:(a) it exhibits antiviral activity against a broad range of RNA viruses;(b) it is currently …